{"id":"dex-21-p","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the action of glucocorticoids, which are steroid hormones that can cause inflammation and suppress the immune system. This can help reduce inflammation and prevent the immune system from attacking healthy tissues.","oneSentence":"Dex 21-P is a glucocorticoid receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:10:28.762Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma","enrollment":53},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":"Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":13},{"nctId":"NCT01171807","phase":"PHASE2","title":"Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis","status":"COMPLETED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2003-07-22","conditions":"Ulcerative Colitis","enrollment":33},{"nctId":"NCT03151811","phase":"PHASE3","title":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","status":"TERMINATED","sponsor":"Oncopeptides AB","startDate":"2017-06-12","conditions":"Multiple Myeloma","enrollment":495},{"nctId":"NCT03679065","phase":"PHASE4","title":"Prophylactic Paracetamol or Dexamethasone for Post-spinal Anesthesia Shivering","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-03-01","conditions":"Shivering","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dexamethasone 21-phosphate"],"phase":"phase_2","status":"active","brandName":"Dex 21-P","genericName":"Dex 21-P","companyName":"Quince Therapeutics S.p.A.","companyId":"quince-therapeutics-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dex 21-P is a small molecule. It is being studied in clinical trials for various types of leukemia, including Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, and Recurrent Chronic Myelogenous Leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}